S&P 500   5,150.83 (-0.93%)
DOW   38,140.93 (-0.83%)
QQQ   440.01 (-1.20%)
AAPL   176.28 (+0.71%)
MSFT   423.42 (-1.05%)
META   516.38 (-1.30%)
GOOGL   158.43 (-0.61%)
AMZN   187.39 (-0.88%)
TSLA   172.52 (-1.19%)
NVDA   890.96 (-1.68%)
AMD   163.98 (-3.82%)
NIO   4.13 (-7.40%)
BABA   72.40 (-3.27%)
T   16.40 (-0.12%)
F   12.68 (-2.76%)
MU   123.18 (-3.40%)
GE   153.99 (-2.17%)
CGC   8.06 (-1.10%)
DIS   114.39 (-2.36%)
AMC   2.70 (-3.57%)
PFE   26.12 (-0.84%)
PYPL   65.25 (-0.84%)
XOM   122.85 (+0.87%)
S&P 500   5,150.83 (-0.93%)
DOW   38,140.93 (-0.83%)
QQQ   440.01 (-1.20%)
AAPL   176.28 (+0.71%)
MSFT   423.42 (-1.05%)
META   516.38 (-1.30%)
GOOGL   158.43 (-0.61%)
AMZN   187.39 (-0.88%)
TSLA   172.52 (-1.19%)
NVDA   890.96 (-1.68%)
AMD   163.98 (-3.82%)
NIO   4.13 (-7.40%)
BABA   72.40 (-3.27%)
T   16.40 (-0.12%)
F   12.68 (-2.76%)
MU   123.18 (-3.40%)
GE   153.99 (-2.17%)
CGC   8.06 (-1.10%)
DIS   114.39 (-2.36%)
AMC   2.70 (-3.57%)
PFE   26.12 (-0.84%)
PYPL   65.25 (-0.84%)
XOM   122.85 (+0.87%)
S&P 500   5,150.83 (-0.93%)
DOW   38,140.93 (-0.83%)
QQQ   440.01 (-1.20%)
AAPL   176.28 (+0.71%)
MSFT   423.42 (-1.05%)
META   516.38 (-1.30%)
GOOGL   158.43 (-0.61%)
AMZN   187.39 (-0.88%)
TSLA   172.52 (-1.19%)
NVDA   890.96 (-1.68%)
AMD   163.98 (-3.82%)
NIO   4.13 (-7.40%)
BABA   72.40 (-3.27%)
T   16.40 (-0.12%)
F   12.68 (-2.76%)
MU   123.18 (-3.40%)
GE   153.99 (-2.17%)
CGC   8.06 (-1.10%)
DIS   114.39 (-2.36%)
AMC   2.70 (-3.57%)
PFE   26.12 (-0.84%)
PYPL   65.25 (-0.84%)
XOM   122.85 (+0.87%)
S&P 500   5,150.83 (-0.93%)
DOW   38,140.93 (-0.83%)
QQQ   440.01 (-1.20%)
AAPL   176.28 (+0.71%)
MSFT   423.42 (-1.05%)
META   516.38 (-1.30%)
GOOGL   158.43 (-0.61%)
AMZN   187.39 (-0.88%)
TSLA   172.52 (-1.19%)
NVDA   890.96 (-1.68%)
AMD   163.98 (-3.82%)
NIO   4.13 (-7.40%)
BABA   72.40 (-3.27%)
T   16.40 (-0.12%)
F   12.68 (-2.76%)
MU   123.18 (-3.40%)
GE   153.99 (-2.17%)
CGC   8.06 (-1.10%)
DIS   114.39 (-2.36%)
AMC   2.70 (-3.57%)
PFE   26.12 (-0.84%)
PYPL   65.25 (-0.84%)
XOM   122.85 (+0.87%)
NYSE:AMAM

Ambrx Biopharma (AMAM) Stock Price, News & Analysis

$28.00
+0.02 (+0.07%)
(As of 03/7/2024)
Today's Range
$27.98
$28.00
50-Day Range
$27.70
$28.00
52-Week Range
$6.55
$28.15
Volume
1.44 million shs
Average Volume
2.12 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.13

Ambrx Biopharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
13.8% Downside
$24.13 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Ambrx Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.45) to ($1.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.19 out of 5 stars

Medical Sector

2737th out of 2,784 stocks

Biological Products, Except Diagnostic Industry

457th out of 465 stocks

AMAM stock logo

About Ambrx Biopharma Stock (NYSE:AMAM)

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

AMAM Stock Price History

AMAM Stock News Headlines

SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
Ambrx Biopharma (NYSE:AMAM) Stock Price Up 0.1%
Johnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash Deal
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
3 Stocks to Buy That Are Up 200% or More in 2024
Ambrx Biopharma just downgraded at JMP Securities, here's why
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
Ambrx Announces Sale to Johnson & Johnson
Ambrix to Join NASDAQ Biotech Index
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
Optimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy Rating
See More Headlines
Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.13
High Stock Price Target
$32.00
Low Stock Price Target
$9.00
Potential Upside/Downside
-13.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.40 million
Book Value
$3.05 per share

Miscellaneous

Free Float
62,746,000
Market Cap
$1.77 billion
Optionable
Optionable
Beta
-1.92
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Daniel J. O'Connor J.D. (Age 59)
    CEO, President & Director
    Comp: $509.94k
  • Ms. Sonja Nelson CPA (Age 51)
    Chief Financial Officer
    Comp: $1.18M
  • Mr. Andrew P. Aromando (Age 55)
    Chief Operating Officer
  • Dr. Ying J. Buechler Ph.D.
    Chief Technology Officer
  • Dr. Shawn Shao-Hui Zhang Ph.D.
    Chief Scientific Officer & GM of China
  • Mr. Jared Kelly
    Senior VP, General Counsel & Corporate Secretary
  • Mr. Robert Azzara
    Vice President of Human Capital
  • Dr. Sandra Aung Ph.D.
    Chief Clinical Officer
  • Ms. Renu Vaish M.Sc. (Age 57)
    Chief Regulatory Officer

AMAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Ambrx Biopharma stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AMAM shares.
View AMAM analyst ratings
or view top-rated stocks.

What is Ambrx Biopharma's stock price target for 2024?

8 Wall Street research analysts have issued 12 month target prices for Ambrx Biopharma's shares. Their AMAM share price targets range from $9.00 to $32.00. On average, they anticipate the company's stock price to reach $24.13 in the next twelve months. This suggests that the stock has a possible downside of 13.8%.
View analysts price targets for AMAM
or view top-rated stocks among Wall Street analysts.

How have AMAM shares performed in 2024?

Ambrx Biopharma's stock was trading at $14.24 at the beginning of 2024. Since then, AMAM shares have increased by 96.6% and is now trading at $28.00.
View the best growth stocks for 2024 here
.

What ETFs hold Ambrx Biopharma's stock?

ETFs with the largest weight of Ambrx Biopharma (NYSE:AMAM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Ambrx Biopharma IPO?

Ambrx Biopharma (AMAM) raised $126 million in an IPO on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen acted as the underwriters for the IPO.

How do I buy shares of Ambrx Biopharma?

Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AMAM) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners